Laropiprant
Combination of | |
---|---|
Hypolipidemic agent | |
Laropiprant | Prostaglandin receptor antagonist |
Clinical data | |
Trade names | Cordaptive, Tredaptive |
AHFS/Drugs.com | UK Drug Information |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
ECHA InfoCard | 100.207.712 |
(what is this?) (verify) |
Clinical data | |
---|---|
Other names | MK-0524A |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Laropiprant (
Merck & Co. planned to market this combination under the trade names Cordaptive in the US and Tredaptive in Europe. Both brands contained 1000 mg of niacin and 20 mg of laropiprant in each tablet.[1]
Mechanism of action
Niacin in cholesterol lowering doses (500–2000 mg per day) causes facial flushes by stimulating biosynthesis of
Taking 325 mg of aspirin 20–30 minutes prior to taking niacin has also been proven to prevent flushing in 90% of patients, presumably by suppressing prostaglandin synthesis,[3] but this medication also increases the risk of gastrointestinal bleeding,[4] though the increased risk is less than 1 percent.[5]
History
In the mid-2000s, in a trial with 1613 patients, 10.2% patients stopped taking the medication in the combination drug group versus 22.2% under niacin monotherapy.[6]
On April 28, 2008, the
On January 11, 2013, Merck & Co Inc. announced they were withdrawing the drug worldwide as a result of European regulators recommendations.[9]
The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) involved more than 25,000 adults. The treatment group received 2 g of extended-release niacin and 40 mg of laropiprant daily. Study results, reported in July 2014, showed that the combination of niacin and laropiprant did not have any beneficial effects when compared with a placebo treatment and had an increase in adverse effects.[10]
References
- ^ a b c "Tredaptive Prescribing Information" (PDF). Merck & Co. Retrieved 2009-11-14.
- S2CID 32102745.
- ^ Kunin RA (1976). "The Action of Aspirin in Preventing the Niacin Flush and its Relevance to the Antischizophrenic Action of Megadose Niacin" (PDF). Orthomolecular Psychiatry. 5 (2): 89–100. Retrieved 2009-11-14.
- S2CID 33742424.
- ^ Paddock C (31 August 2009). "For Healthy People Daily Aspirin May Do More Harm Than Good". Medical News Today.
- S2CID 2126240.
- BusinessWeek. Archived from the originalon May 2, 2008. Retrieved 2009-11-13.
- ^ "Tredaptive European Public Assessment Report" (PDF). European Medicines Agency. Retrieved November 13, 2009.
- ^ "Merck withdraws cholesterol drug Tredaptive globally". Reuters. January 11, 2013. Retrieved 11 January 2013.[dead link]
- S2CID 23548060.